Therapeutic options for cognitive decline in senior pets

Journal of the American Animal Hospital Association

Volumn 42, Issue 6, 2006, Pages 407-413

  Landsberg, Gary ^a  

^a Doncaster Animal Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947128530     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0420407     Document Type: Article

References (76)

1. Landsberg GM, Hunthasuen W, Ackerman L. The effects of aging on the behavior of senior pets. In: Landsberg GM, Hunthausen W, Ackerman L, eds. Handbook of Behavior Problems of the Dog and Cat. 2nd ed. Edinburgh: Saunders, 2003:269-304.
2. Landsberg GM, Araujo J. Behavior problems in geriatric pets. Vet Clin North Am Small Anim Pract 2005;35:675-698.
3. Landsberg GM, Head E. Aging and effects on behavior. In: Hoskins JD, ed. Geriatrics and Gerontology of the Dog and Cat. 2nd ed. St. Louis: Elsevier Saunders, 2004:29-42.
4. Epstein M, Kuehn N, Landsberg G, et al. AAHA Senior Care Guidelines for Dogs and Cats. J Am Anim Hosp Assoc 2005;41:81-91.
5. Nielson JC, Hart BL, Cliff KD, et al. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc 2001;218:1787-1791.
6. Borras D, Ferrer I, Pumarola M. Age-related changes in the brain of the dog. Vet Pathol 1999;36:202-211.
7. Cummings BJ, Satou T, Head E, et al. Diffuse plaques contain c-terminal AB42 and not AB40: evidence from cats and dogs. Neurobiol Aging 1996;17:4653-4659.
8. Head E, Liu J, Hagen TM, et al. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82:375-381.
9. Adams B, Chan A, Callahan H, et al. The canine as a model of human cognitive aging: recent developments. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:675-692.
10. Colle MA, Hauw JJ, Crespeau F, et al. Vascular and parenchymal A-beta deposition in the aging dog: correlation with behaviour. Neurobiol Aging 2000;21:695-704.
11. Cummings BJ, Head E, Afagh AJ, et al. B-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiology Learn Mem 1996;66:11-23.
12. Milgram NW, Zicker SC, Head EA, et al. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 2002;23:737-745.
13. Adams B, Chan A, Callahan H, et al. Use of a delayed non-matching to position task to model age-dependent cognitive decline in the dog. Behav Brain Res 2000;108:47-56.
14. Studzinski CM, Christie LA, Araujo JA, et al. Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human cognitive aging and dementia. Neurobiology Learn Mem 2006; 197-204.
15. Tapp PD, Siwak CT, Estrada J, et al. Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem 2003;10:64-73.
16. Tapp PD, Siwak CT, Gao FQ, et al. Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci 2004;24:8205-8213.
17. Siwak CT, Tapp PD, Milgram NW. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem 2001;8:65-70.
18. Araujo JA, Studzinski CM, Head E, et al. Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging. AGE 2005;27:27-37.
19. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements - The Cache County Study. Arch Neurol 2004;61:82-88.
20. Standridge JB. The pharmacologic prevention of Alzheimer's disease. Alzheimer's and Dementia 2005;1:64.
21. Kidd PM. Neurodegeneration from mitochondrial insufficiency; nutrients, stem cells, growth factors, and prospects for brain rebuilding through integrative management. Altern Med Rev 2005;10:268-293.
22. Rofina JE, Singh K, Skolumalova-Vesela, et al. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 2004;11:90-100.
23. Skoumalova A, Rofina J, Schwippelova Z, et al. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 2003;38:711-719.
24. Kealy RD, Lawler DF, Ballam JM, et al. Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 2002;220:1315-1320.
25. Cotman CW, Head E, Muggenburg BA, et al. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 2002;23:809-818.
26. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversals of age-related declines in neuronal signal transduction, cognitive, motor and behavioral deficits with blueberry, spinach and strawberry dietary supplementation. J Neurosci 1999;19:8114-8121.
27. Martin A, Prior R, Shukitt-Hale B, et al. Effect of fruits, vegetables, or vitamin E-rich diet on vitamins E and C distribution in peripheral and brain tissues: implications for brain function. Gerontol A Biol Sci Med Sci 2000;55:144-151.
28. Ikeda-Douglas CJ, Zicker SC, Estrada J, et al. Prior experience, antioxidants, and mitochondrial co-factors improve cognitive dysfunction in aged beagles. Vet Therapeut 2004;5:5-16.
29. Fryer MJ. Vitamin E status and neurodegenerative disease. Nutr Neurosci 1998;1:327-351.
30. McGahon BM, Martin DSD, Horrobin DF, et al. Age-related changes in LTP and antioxidant defenses are reversed by an α-lipoic acid-enriched diet. Neurobiol Aging 1999;20:655-664.
31. Hagen TM, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci 2002;99:870-875.
32. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000;18:383-399.
33. Milgram NW, Head E, Muggenburg B, et al. Landmark discrimination learning in the dog; effects of age, an antioxidant fortified food, and cognitive strategy. Neurosci Biobehav Rev 2002;26:679-695.
34. Milgram NW, Head E, Zicker SC, et al. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp Gerontol 2004;39:753-765.
35. Dodd CE, Zicker SC, Jewell DE, et al. Can a fortified food affect the behavioral manifestations of age-related cognitive decline in dogs? Vet Med 2003;98:396-408.
36. Osella MC, Re G, Odore R, et al. Canine cognitive dysfunction: prevalence, clinical signs and treatment with a nutraceutical. In: Mills D, Levine E, Landsberg GM, et al., eds. Current Issues and Research in Veterinary Behavioral Medicine. West Lafayette IN: Purdue University Press, 2005:66-72.
37. Cena F, Colangeli R, Fassola F, et al. Effect of a combination of phosphatidylserine, ginkgo biloba, vitamin E and pyridoxine on clinical signs of brain aging; a pilot multicentric study. Proc Europ Coll Vet Behav Med Companion Anim 2005;2:127-135.
38. Heath SE, Barabas S, Craze PG. Nutritional supplementation in cases of canine cognitive dysfunction; results of a clinical trial. In: Mills D, Levine E, Landsberg GM, et al., eds. Current Issues and Research in Veterinary Behavioral Medicine. West Lafayette IN: Purdue University Press, 2005:73-77.
39. Landsberg G, Araujo J. The effects of a proprietary nutraceutical on short-term memory performance on aged dogs. Proc Am Coll Vet Behav, Honolulu, 2006:49-54.
40. Samson JC. The biological basis of phosphatidylserine pharmacology. Clin Trials J 1987;24:1-8.
41. Tsakiris S, Deliconstantinos G. Phosphatidylserine and calmodulin effects on Ca2+-stimulated ATPase activity of dog brain synaptosomal plasma membranes. Int J Biochem 1985;17:1117-1119.
42. Cenacchi T, Bertoldin T, Farina C. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging Clin Exp Res 1993;5:123-133.
43. Suzuki S, Yamatoya H, Sakai M. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. J Nutr 2001;131:2951-2956.
44. Vannucchi MG, Casamenti F, Pepeu G. Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine. J Neurochem 1990;55:819-825.
45. Yamatoya H, Sakai M, Kudo S. The effects of soybean transphosphatidylated phosphatidylserine on cholinergic synaptic functions of mice. Jpn J Pharmacol 2000;84:93-96.
46. Gelbmann CM, Muller WE. Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain. Neurobiol Aging 1992;13:45-50.
47. Raitieri M, Caviglia AM, Marchi M, et al. Changes of neurotransmitter release in the old rat brain and effects of phosphatidylserine treatment. In: Pepeu G, Tomlinson B, Wischik CM, eds. New Trends in Aging Research. Padua: Liviana Press, 1988:21-26.
48. Araujo JA, Chan AD, Winka LL, et al. Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. Pyschopharmacology (Berl) 2004;175:92-98.
49. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Psychopharmacol Biol Psychiatry 2005;29:411-422.
50. White HL, Scates PW, Cooper BR. Extracts of ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996;58:1315-1321.
51. Le Bars PL, Velasco FM, Ferguson JM. Influence of the severity of cognitive impairment on the effect of the ginkgo biloba Egb761 in Alzheimer's disease. Neuropsychobiology 2002;45:19-26.
52. Hoffman JR, Donato A, Robbins SJ. Ginkgo biloba promotes short-term retention of spatial memory in rats. Pharmacol Biochem Behav 2004;77:533-539.
53. Bastianetto S, Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol Aging 2002;23:891-897.
54. Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1A receptors during aging: reversal by ginkgo biloba extract (EGb 761). J Pharm Pharmacol 1994;46:316-318.
55. Lee TF, Chen CF, Wang LC. Effect of ginkgolides on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices. Phytother Res 2004;18:556-560.
56. Ahlemeyer B, Krieglstein J. Neuroprotective effects of ginkgo biloba extract. Cell Mol Life Sci 2003;60:1779-1792.
57. Dakshinamurti K, Paulose CS, Siow YL. Neurobiology of pyridoxine. In: Reynolds RD, Leklem JE, eds. Vitamin B6: Its Role in Health and Disease. New York: Alan R Liss, 1995:99-121.
58. Sano M, Ernesto C, Thomas RG. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;17:1216-1222.
59. Pocernich CB, La Fontaine M, Butterfield DA. In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int 2000;36:185-191.
60. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid. Pharmacol Res 1999;40: 211-215.
61. Campbell S, Trettien A, Kozan B. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Therapeut 2001;2:24-39.
62. Dehasse J. Retrospective study on the use of selegiline (Selgian) in cats. Proc Am Vet Soc Anim Behav, New Orleans, 1999.
63. Milgram NW, Ivy GO, Head E, et al. The effect of l-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Neurochem Res 1993;18:1211-1219.
64. Knoll J. L-Deprenyl (selegiline) - a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 1998;82:57-66.
65. Carillo M-C, Ivy GO, Milgram NW, et al. Deprenyl increases activity of superoxide dismutase. Life Sci 1994;54:1483-1489.
66. Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurol Scand 1991;84 (Suppl 136):44-59.
67. Peremans K, Audenaert K, Blanckaert P, et al. Effects of aging on brain perfusion and serotonin-2A receptor binding in the normal canine brain measured with single photon emission tomography. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1393-1404.
68. Penaliggon J. The use of nicergoline in the reversal of behavioural changes due to aging in dogs: a multicentre clinical field trial. Proc Inter Conf Behav Med, Herts, UK 1997;1:37-41.
69. Kapl D, Rudolphi KA. New pharmacological aspects in the neurologic profile of propentofylline (Karsivan). Vet Tierarztl Prax Ausg Klientiere Heimtiere 1998;26:317-321.
70. Milgram NW, Siwak CT, Gruet P, et al. Oral administration of adrafinil improves discrimination learning in aged beagle dogs. Pharmacol Biochem Behav 2000;66:301-305.
71. Siwak CT, Gruet P, Woehrle F, et al. Comparison of the effects of adrafinil, propentofylline and nicergoline on behavior in aged dogs. Am J Vet Res 2000;61:1410-1414.
72. Matsui K, Taniguchi S, Yoshimura T. Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. Xenobiotica 1999;29:1059-1072.
73. Monbaliu J, Verhaeghe T, Willems B, et al. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung 2003;53:486-495.
74. Tapp PD, Siwak CT, Head E, et al. Sex differences in the effect of oestrogen on size discrimination learning and spatial memory. Proc Inter Cong Vet Behav Med, Wheathampsead, UK 2001;3:136-138.
75. Hart BL. Effect of gonadectomy on subsequent development of age-related cognitive impairment in dogs. J Am Vet Med Assoc 2001;219:51-56.
76. Pike CJ, Rosario ER, Nguyen TV. Androgens, aging and Alzheimer's disease. Endocrine 2006;2:233-242.